Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Hupperts

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pageof 12